Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by Stanford University.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University
ClinicalTrials.gov Identifier:
NCT00780494
First received: October 23, 2008
Last updated: September 3, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2014
  Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)